Following authorization from Health Canada, in-warranty pump users can access full compatibility with the G7 and G6 CGMs. This makes t:slim X2 the first and only pump integrated with both continuous glucose monitors in Canada. Tandem first announced the integration — which already exists on the U.S. market — in July.
“The commercial availability of this new offering is a testament to our decade-long partnership with Dexcom and shared commitment to continued leadership in advancing AID systems,” said Mark Novara, EVP and CCO of Tandem Diabetes Care. “Now, our t:slim X2 users in Canada can have access to a range of innovative tools that not only simplify diabetes management but also enhance their quality of life.”
Dexcom’s G7 CGM features a 60% size reduction from G6 and offers a 30-minute warmup period (down from waiting two hours for glucose readings to begin in the past). G7 provides more information in one place with personalized insights, extended-wear design and more. It features a simple wear experience, starting with unscrewing a cap. The user then puts the sensor on their body and pushes a button. The device is then turned on and can be paired with a smartphone.
Tandem’s t:slim X2 pump uses CGM data to predict glucose levels 30 minutes ahead and automatically adjust insulin if needed. It offers customizable personal profiles and optional settings for sleep or exercise activity. Tandem also offers a variety of on-body infusion sets for more convenience and flexibility.
“Through our continued partnership with Tandem, we have seen the proven benefits of automated insulin delivery. We’re proud that people living in Canada can now access the latest AID offering with Dexcom G7, our smallest and most accurate CGM,” said André Côté, EVP and GM of Dexcom Canada. “Our two organizations hold the same core value: foster technological innovation that leads to a better life for those living with diabetes. We couldn’t be more pleased to officially bring this offering to Canadians.”
